Shire faces 5 separate court cases on the 720 patent. They won against Watson last spring after an appeal that went all the way to the Supreme court. Now, negative news out late Friday. Then there's an IPR of the drug launched by Kyle Bass that the PTAB will rule on next month. It seems like a never-ending battle. I guess the good news is that now, after the Baxalta buyout, Lialda revenues are a smaller percentage of total.
@@@Shire plc was informed today that the United States District Court for the District of Delaware has ruled that Cadilla Healthcare Ltd./Zydus Pharmaceuticals (USA) Inc.'s proposed generic version of Lialda does not infringe U.S Patent No. 6,773,720.
@@@Shire plc was informed today that the United States District Court for the District of Delaware has ruled that Cadilla Healthcare Ltd./Zydus Pharmaceuticals (USA) Inc.'s proposed generic version of Lialda does not infringe U.S Patent No. 6,773,720.